454 Life Sciences, a majority-owned subsidiary of CuraGen Corporation , today announced the achievement of all initial milestones under their exclusive world-wide agreement with Roche, bringing the total milestone payments received by 454 Life Sciences from Roche to $11.5 million. "We are very pleased to have accomplished these initial milestones as these activities have laid the foundation for the commercial launch of 454 Life Sciences' Genome Sequencing Systems and reagents by Roche," stated Christopher K. McLeod, President and Chief Executive Officer of 454 Life Sciences. "In addition to enabling the commercial launch with Roche, these milestones triggered payments which we believe will advance us toward our goal of financial self-sufficiency."

Posted by GEN-ERIC at 02:31:06 am into the following categories: In The News

---

http://gen-eric.com/patents/htsrv/trackback.php/314

Name:

Email: (not displayed on this site)

Site/Url:

Comment text:

Allowed XHTML tags: <p, ul, ol, li, dl, dt, dd, address, blockquote, ins, del, a, span, bdo, br, em, strong, dfn, code, samp, kdb, var, cite, abbr, acronym, q, sub, sup, tt, i, b, big, small>

URLs, email, AIM and ICQs will be converted automatically.

Options:
Auto-BR (Line breaks become <br />)
Remember me (Set cookies for name, email & url)